ECSP21081726A - Inhibidores de dihidroorotato deshidrogenasa - Google Patents

Inhibidores de dihidroorotato deshidrogenasa

Info

Publication number
ECSP21081726A
ECSP21081726A ECSENADI202181726A ECDI202181726A ECSP21081726A EC SP21081726 A ECSP21081726 A EC SP21081726A EC SENADI202181726 A ECSENADI202181726 A EC SENADI202181726A EC DI202181726 A ECDI202181726 A EC DI202181726A EC SP21081726 A ECSP21081726 A EC SP21081726A
Authority
EC
Ecuador
Prior art keywords
dehydrogenase inhibitors
dihydroorotate dehydrogenase
dihydroorotate
inhibitors
attached
Prior art date
Application number
ECSENADI202181726A
Other languages
English (en)
Inventor
Scott Kuduk
Aihua Wang
Zhuming Zhang
Lindsey Deratt
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of ECSP21081726A publication Critical patent/ECSP21081726A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se acompaña resumen
ECSENADI202181726A 2019-04-17 2021-11-16 Inhibidores de dihidroorotato deshidrogenasa ECSP21081726A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962835113P 2019-04-17 2019-04-17

Publications (1)

Publication Number Publication Date
ECSP21081726A true ECSP21081726A (es) 2021-12-30

Family

ID=70465152

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202181726A ECSP21081726A (es) 2019-04-17 2021-11-16 Inhibidores de dihidroorotato deshidrogenasa

Country Status (22)

Country Link
US (2) US11505536B2 (es)
EP (1) EP3956320B1 (es)
JP (1) JP2022530203A (es)
KR (1) KR20220002964A (es)
CN (1) CN114174278A (es)
AR (1) AR118724A1 (es)
AU (1) AU2020259384A1 (es)
BR (1) BR112021020520A2 (es)
CA (1) CA3136791A1 (es)
CL (1) CL2021002681A1 (es)
CO (1) CO2021015264A2 (es)
CR (1) CR20210520A (es)
EC (1) ECSP21081726A (es)
ES (1) ES2968809T3 (es)
IL (1) IL287268A (es)
MA (1) MA55716A (es)
MX (1) MX2021012706A (es)
PE (1) PE20220761A1 (es)
SG (1) SG11202111179RA (es)
TW (1) TW202104207A (es)
UY (1) UY38670A (es)
WO (1) WO2020212897A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116457343A (zh) * 2020-07-14 2023-07-18 南京征祥医药有限公司 作为dhodh抑制剂的化合物
WO2022070068A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2022074534A1 (en) * 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
EP4313150A1 (en) 2021-03-26 2024-02-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Pyrimidine biosynthesis inhibitor combination for use in treating viral infections
PE20240588A1 (es) 2021-05-11 2024-03-21 Janssen Pharmaceutica Nv Terapias de combinacion
JP2024518497A (ja) 2021-05-11 2024-05-01 ヤンセン ファーマシューティカ エヌ.ベー. 併用療法
TW202333689A (zh) * 2021-10-13 2023-09-01 美商雷密克斯醫療公司 調節剪接之化合物及方法
AR127621A1 (es) * 2021-11-09 2024-02-14 Vigil Neuroscience Inc Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1726585A4 (en) 2004-03-05 2009-07-15 Banyu Pharma Co Ltd HETEROCYCLIC DERIVATIVE WITH FIVE ELEMENTS SUBSTITUTED BY A DIARYLE
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
RS60002B1 (sr) * 2013-10-18 2020-04-30 Celgene Quanticel Research Inc Inhibitori bromodomena
CN107001328B (zh) * 2014-09-19 2020-06-05 福马治疗股份有限公司 作为突变型异柠檬酸脱氢酶抑制剂的吡啶-2(1h)-酮喹啉酮衍生物
BR112017013149B1 (pt) 2014-12-18 2022-10-11 Takeda Pharmaceutical Company Limited Composto, composição farmacêutica e uso dos mesmos
EP3532474B1 (en) 2016-10-27 2024-03-27 Bayer AG 4,5-annulated 1,2,4-triazolones
JOP20190094A1 (ar) * 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
US11028054B2 (en) 2017-02-24 2021-06-08 Merck Patent Gmbh 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
CA3094104A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite
TW202043208A (zh) 2019-01-11 2020-12-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
AU2020218154A1 (en) * 2019-02-07 2021-08-05 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors

Also Published As

Publication number Publication date
BR112021020520A2 (pt) 2021-12-07
UY38670A (es) 2020-10-30
CN114174278A (zh) 2022-03-11
EP3956320A1 (en) 2022-02-23
CL2021002681A1 (es) 2022-05-27
JP2022530203A (ja) 2022-06-28
AR118724A1 (es) 2021-10-27
TW202104207A (zh) 2021-02-01
PE20220761A1 (es) 2022-05-16
KR20220002964A (ko) 2022-01-07
CO2021015264A2 (es) 2021-11-19
MX2021012706A (es) 2022-01-31
CA3136791A1 (en) 2020-10-22
CR20210520A (es) 2021-12-20
US20220298137A1 (en) 2022-09-22
IL287268A (en) 2021-12-01
US20200331881A1 (en) 2020-10-22
AU2020259384A1 (en) 2021-11-11
US11753393B2 (en) 2023-09-12
MA55716A (fr) 2022-02-23
US11505536B2 (en) 2022-11-22
ES2968809T3 (es) 2024-05-14
EP3956320B1 (en) 2023-11-29
WO2020212897A1 (en) 2020-10-22
SG11202111179RA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
ECSP21081726A (es) Inhibidores de dihidroorotato deshidrogenasa
CL2022001670A1 (es) Inhibidores de proteínas kras mutantes
CO2019003709A2 (es) Conjugados de pirrolobenzodiazepina
MA54695A (fr) Inhibiteurs de dihydroorotate déshydrogénase
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
IL284989A (en) Dihydrourotate dehydrogenase inhibitors
CL2021002182A1 (es) Formulación de anticuerpos terapéuticos
TWD200597S (zh) 捲尺
ES2970180T3 (es) Inhibidores de la dihidroorotato deshidrogenasa bi-arilo
CR20210463A (es) Inhibidores de arginasa y métodos de uso de estos
ECSDI20008419S (es) Pelador de mano
UY4960S (es) Cartera-matera
JP1727430S (ja) オフィスビル
UY4872S (es) Zapatos
CL2018002625S1 (es) Refrigerador
ECSDI21053496S (es) Colgante dual
AR128365A1 (es) Inhibidores de parp7
CL2022003127S1 (es) Recipiente
CL2022003125S1 (es) Recipiente
CL2022003123S1 (es) Recipiente
CL2022003122S1 (es) Recipiente
CL2022003126S1 (es) Recipiente
JP1740342S (ja)
JP1740341S (ja)